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ABSTRACT: Gamma (γ)-glutamyl carboxylase (GGCX) is an integral
membrane protein responsible for the post-translational catalytic
conversion of select glutamic acid (Glu) residues to γ-carboxy glutamic
acid (Gla) in vitamin K-dependent (VKD) proteins. Understanding the
mechanism of carboxylation and the role of GGCX in the vitamin K cycle
is of biological interest in the development of therapeutics for blood
coagulation disorders. Historically, biophysical investigations and
structural characterizations of GGCX have been limited due to
complexities involving the availability of an appropriate model membrane
system. In previous work, a hydrogen exchange mass spectrometry (HX
MS) platform was developed to study the structural conﬁguration of GGCX in a near-native nanodisc phospholipid environment.
Here we have applied the nanodisc−HX MS approach to characterize speciﬁc domains of GGCX that exhibit structural
rearrangements upon binding the high-aﬃnity consensus propeptide (pCon; AVFLSREQANQVLQRRRR). pCon binding was
shown to be speciﬁc for monomeric GGCX-nanodiscs and promoted enhanced structural stability to the nanodisc-integrated
complex while maintaining catalytic activity in the presence of carboxylation co-substrates. Noteworthy modiﬁcations in HX of
GGCX were prominently observed in GGCX peptides 491−507 and 395−401 upon pCon association, consistent with regions
previously identiﬁed as sites for propeptide and glutamate binding. Several additional protein regions exhibited minor gains in
solvent protection upon propeptide incorporation, providing evidence for a structural reorientation of the GGCX complex in
association with VKD carboxylation. The results herein demonstrate that nanodisc−HX MS can be utilized to study molecular
interactions of membrane-bound enzymes in the absence of a complete three-dimensional structure and to map dynamic
rearrangements induced upon ligand binding.
Vitamin K-dependent γ-glutamyl carboxylase (GGCX) is a758-amino acid integral membrane glycoprotein1 with ﬁve
transmembrane domains and a disulﬁde bond between residues
99 and 450.2,3 Topological studies reveal that each trans-
membrane domain passes through the endoplasmic reticulum
(ER) with the N-terminus of the protein in the cytoplasm and
C-terminus in the lumen.2 In the presence of co-substrates
vitamin K hydroquinone (KH2), oxygen, and carbon dioxide
GGCX modiﬁes select glutamic acid (Glu) residues to γ-
carboxy glutamic acid (Gla) in vitamin K-dependent (VKD)
proteins. Concomitant with VKD carboxylation and the
formation of vitamin K 2,3-epoxide (KO) is the catalytic
regeneration of KH2 involving vitamin K epoxide reductase
(VKOR). As a result of the interdependence of proteins in the
vitamin K cycle, depletion of KH2 and consequently reduced
carboxylation are shown to result when VKOR is inhibited by
Warfarin, a commonly used anticoagulant.4
GGCX recognizes VKD protein substrates through an 18-
amino acid region, termed the propeptide. An alignment of
multiple propeptide sequences is illustrated in Supplemental
Figure S1, Supporting Information where the height of stacked
amino acids indicates the frequency of that amino acid at a
particular position.5,6 If one of the highly conserved amino acid
residues (phenylalanine at −16, alanine at −10, or leucine at
−6) is mutated, substrate carboxylation is diminished or
eliminated, under most circumstances.7,8 Despite the high
degree of propeptide sequence homology, substrate binding
aﬃnity to GGCX varies over 100-fold with the consensus and
factor X propeptides showing the highest aﬃnity (lowest Kd)
and prothrombin the lowest aﬃnity.9 The explanation for this
variability is not yet known; however, the binding of a VKD
protein to GGCX is concluded to be a cooperative event
between the propeptide and the Gla domain.10
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Current understanding suggests the propeptide region tightly
binds GGCX between residues 495−51311,12 initiating a
structural reorientation by which the Gla domain of the VKD
substrate (approximately 45 amino acids)13−15 is positioned at
the catalytic active site of GGCX. In the presence of KH2, select
glutamic acid residues in the Gla domain are carboxylated to γ-
carboxy glutamic acid. Carboxylation of the VKD protein
continues in a processive manner whereby all impending
carboxylations for a given Gla domain take place in a single
binding event.16,17 Once GGCX converts the selected Glu
residues in the VKD protein to Gla residues, the propeptide is
proteolytically excised and the protein is secreted from the
cell.18 In the presence of calcium, the mature VKD protein
undergoes a conformational reorientation allowing association
with phospholipids on the membrane surface near damaged
vascular tissue. An elegant theory explaining the mechanism of
carboxylation using a base ampliﬁcation chemical model was
proposed by Dowd and colleagues.19 That work spawned
decades of mutational studies3,20−27 and quantum model-
ing28−30 in search of potential GGCX active site residues shown
to aﬀect enzymatic activity.
Important clues concerning the location of the glutamate
binding site in GGCX have come from a naturally occurring
mutant form of GGCX with a point mutation at position 394
(L394R).31,32 Patients with this mutation exhibit decreased
coagulation activity of VKD clotting factors resulting in bleeding
diathesis. In vitro substitutions of L394 and neighboring residues
Y395 and W399 resulted in defective glutamate binding and
signiﬁcant inhibition of carboxylation.32 That work provided
evidence that glutamate recognition is the primary function of
the highly conserved domain between residues 393−404 in
GGCX. In addition to playing a major role in the binding of the
glutamate substrate, L394R and W399A were also shown to be
involved in the propeptide binding.32
Extensive research has been conducted on the biochemistry
of GGCX, as described above, yet unraveling the structural
associations of protein complexes in the vitamin K cycle has
been severely limited due to complexities in sample preparation
including protein aggregation, oligomerization, or precipitation
in solution. To surmount the challenges of investigating the
structural characterization of GGCX, hydrogen exchange mass
spectrometry (HX MS) of membrane protein-embedded
nanodiscs has recently been reported.33 Formation of nanodiscs
is an empirical process that, when optimized, promotes
stabilization of a target membrane protein into a nanoscale
phospholipid bilayer encompassed by an amphipathic mem-
brane scaﬀold protein (MSP). Previous studies investigating
membrane proteins by HX MS have been reported using lipid
vesicles or detergent micelles.34−41 The use of nanodiscs,
however, enables selective labeling methods such as hydrogen
exchange to occur within an environment that mimics native
membrane conditions. In this paper, we report nanodisc−HX of
GGCX as compared with nanodisc−HX of GGCX−propeptide
complexes. Comparing deuterium uptake signatures for GGCX
with and without the presence of propeptide provides a
dynamic visual mapping of localized structural ﬂuctuations upon
binding to the substrate. Utilizing HX MS to investigate
membrane protein−ligand interactions in controlled single-
molecule nanodisc environments uniquely enables investigation
of conformational changes in membrane proteins induced by
substrate, drug, or protein interactions.
■ EXPERIMENTAL PROCEDURES
GGCX Puriﬁcation. Wild-type human GGCX with a
carboxyl-terminal 12-amino acid epitope tag (EDQVDPRL-
IDGK) was isolated from Sf 9 cells, as previously described.9
Solubilized GGCX microsomes were puriﬁed using a calcium-
dependent HPC4 antibody resin (Dr. Charles T. Esmon,
Cardiovascular Biology Research Program, Oklahoma Medical
Research Foundation, Oklahoma City, OK)42 and eluted in 25
mM MOPS pH 7.5, 0.1 M NaCl, 15% glycerol, 0.5% CHAPS,
0.2% 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and
10 mM EDTA, stabilized by a protease inhibitor cocktail
(aprotinin, leupeptin, pepstatin, and phenylmethylsulfonyl
ﬂuoride). DOPC phospholipid was purchased from Avanti
Polar Lipids (Alabaster, AL), and protease inhibitors were from
Roche Applied Science (Indianapolis, IN). Puriﬁed protein was
stored at −80°C. Protein concentration and purity were
determined by enzymatic activity assay measurements and
SDS-PAGE.
Membrane Scaﬀold Protein (MSP1D1) Expression and
Puriﬁcation. MSP1D1 expression and puriﬁcation were
performed as previously described.43 Brieﬂy, the MSP1D1
plasmid with a polyhistidine tag (Addgene plasmid 20061) was
expressed in Escherichia coli BL21 Codon Plus (DE3) cells. The
protein was isolated by Ni-NTA Agarose (QIAGEN, Valencia,
CA) aﬃnity puriﬁcation, and purity was conﬁrmed by
polyacrylamide gel electrophoresis (PAGE). Fractions contain-
ing MSP1D1 were pooled and dialyzed against standard buﬀer
(20 mM Tris-HCl pH 7.4, 0.1 M NaCl, 0.5 mM EDTA, and
0.01% NaN3). Puriﬁed protein was lyophilized and stored at
−20°C. Protein concentration was determined by absorbance at
280 nm us ing ca lcu la ted ext inct ion coeﬃc ients
(ε280nm = 21000 M
−1 cm−1 for MSP1D1).
Self-Assembly of Nanodiscs. Self-assembly of GGCX-
nanodiscs was initiated as previously reported.33 Phospholipid
stock solutions were prepared in chloroform, and the
concentration was determined by phosphate analysis.44,45 A
DOPC/deoxycholate (2:1) solubilized mixture was added to
the puriﬁed microsomal GGCX target protein. The equilibrated
mixture was added to an excess of puriﬁed MSP1D1 and 50 mM
Tris-HCl pH 7.4, 0.15 M NaCl, and 0.02% NaN3 (TBS) buﬀer.
Samples were incubated at 4°C. Self-assembly was initiated
upon detergent removal during a 2 h gentle rotation with damp
SM-2 BioBeads (BioRad, Hercules, CA). For GGCX-nanodisc
preparations in the presence of consensus propeptide [pCon]
(AVFLSREQANQVLQRRRR) or ﬂuorescein-labeled consen-
sus propeptide [FpCon] (Fl-AVFLSREQANQVLQRRRR), the
reaction mixture was ﬁrst incubated with a 10-fold excess of
propeptide for 45 min at 4°C prior to the addition of solubilized
phospholipid.
Nanodisc preparations were puriﬁed by size-exclusion
chromatography (SEC) monitoring the absorbance of the
sample eluent at 280 nm. Separation was completed on a Tosoh
TSKgel BioAssist G3SWXL 7.8 × 300 mm (5 μm particles, 250
Å) column using 50 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.02%
NaN3 (TBS) mobile phase at 0.5 mL/min. Fractions containing
puriﬁed GGCX-nanodiscs were isolated and concentrated by
Millipore (Bedford, MA) Microcon YM-30 centrifugal ﬁlters.
Puriﬁed nanodiscs were stored at 4°C for up to one month.
Protein concentration and purity were determined by enzymatic
activity assay measurements and SDS-PAGE.
SDS-PAGE. Puriﬁed nanodiscs were analyzed by SDS-PAGE
on NuPAGE Novex 4−12% Bis−Tris gradient gels (Invitrogen
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Life Sciences, Grand Island, NY). SDS-PAGE buﬀers were
prepared according to a protocol derived from Invitrogen Life
Sciences including a 4× SDS-PAGE loading buﬀer and a 20×
MES running buﬀer. PAGE gels were stained using SYPRO
Ruby stain (Invitrogen Life Sciences) and imaged using a 300
nm blue light UV transilluminator (Alpha Innotech AlphaIm-
ager 2200) with interference wavelength ﬁltering. For protein
molecular weight referencing, the Mark 12 unstained protein
ladder (Invitrogen Life Sciences) was loaded on each gel.
In Vitro Carboxylation. GGCX in vitro activity was
determined by measuring the carboxylation of a synthetic
pentapeptide substrate FLEEL (Phe-Leu-Glu-Glu-Leu) in the
presence of excess factor IX propeptide [pFIX] (TVFLD-
HENANKILNRPKR) or incorporated consensus propeptide
[pCon] (AVFLSREQANQVLQRRRR) and co-substrates KH2,
oxygen, and radiolabeled CO2 in the form of NaH
14CO3
(speciﬁc activity 55 mCi/mmol; MP Biomedicals, Solon,
OH). Vitamin K1(25) phylloquinone, detergent-stabilized
emulsion (Hospira Incorporated, Lake Forest, IL), or vitamin
K3 menadione, water-soluble sodium bisulﬁte analogue, (Sigma
Aldrich, St. Louis, MO) was utilized in reaction mixtures
containing microsomal GGCX or GGCX-embedded nanodiscs,
respectively. Vitamin K was reduced to KH2 by overnight
incubation with buﬀer containing 25 mM Tris-HCl pH 8.5, 0.5
M NaCl, and 0.2 M dithiothreitol at 37°C.
The reagent mixture (25 mM MOPS pH 7.5, 0.50 M NaCl,
CHAPS, DOPC, 30 mM FLEEL, and 2.4 μM pFIX) was
allowed to incubate with microsomal GGCX or GGCX-
nanodiscs for 30 min on ice. The concentration of CHAPS
and DOPC in the assay reaction mixture was modiﬁed to
optimize conditions for sample carboxylation such that 0.16%
CHAPS/DOPC was incorporated into the assay reconstitution
mixture for microsomal GGCX, and no additional CHAPS/
DOPC was included for assays evaluating GGCX-nanodiscs. An
excess of 222 μM (5.5 mM stock) KH2 phylloquinone or 111
μM (2.75 mM stock) KH2 menadione with 5 μL of an 18.4 mM
NaH14CO3 stock solution was added to the reaction mixture for
a ﬁnal volume of 125 μL. The carboxylation assay was allowed
to proceed for 120 min at 20°C. The carboxylated product was
precipitated with 5% trichloroacetic acid and boiled to remove
excess 14CO2. The radioactivity was determined by scintillation
counting (Beckman LS5000TD).
Hydrogen Exchange Mass Spectrometry. Deuterium
exchange of GGCX-embedded nanodiscs was carried out as
described previously.33 A total of 50 pmol of GGCX-nanodiscs
(100 pmol of MSP1D1; 6 nmol of DOPC) was diluted 10-fold
in 99% deuterium oxide buﬀer (50 mM Tris-HCl, 0.15 M NaCl,
0.02% NaN3, D2O, pD 7.0) at room temperature. At times
ranging from 10 s to 4 h after the introduction of D2O, the
sample was quenched to pH 2.5 by the addition of formic acid
and placed on ice. To retain the deuterium that exchanged into
the protein, the sample was maintained under quench
conditions (pH 2.5; 0°C) for all sample handling steps prior
to analysis by mass spectrometry.46 Upon quenching, nanodiscs
were immediately disassembled with the addition of 25:1
sodium cholate/DOPC. Digestion was completed for 5 min on
ice with porcine pepsin-immobilized Poros 20AL resin (Applied
Biosystems, Carlsbad, CA).47 In the last minute of digestion, 3
mg of ZrO2-coated silica resin was added to the digestion
mixture to remove DOPC phospholipids. The sample was
passed across a chilled ﬁlter (0.45 μm cellulose acetate) by
centrifugation at 4°C for 1 min and loaded immediately onto a
refrigerated UPLC-MS system for chromatography and mass
spectral analysis. Empty nanodiscs and GGCX-pCon-nanodiscs
were analyzed in a similar manner. For puriﬁed propeptide, 25
μL of a 2 μM solution was used in the continuous labeling HX
reaction. The digestion protocol followed that of the nanodisc
procedure as outlined above.
Chromatography was completed on a Waters nanoAcquity
UPLC system (Milford, Massachusetts) designed for HX MS.48
The peptic peptides were trapped on a Waters VanGuard
column packed with 1.7 μm C18 particles (2.1 mm × 5.0 mm)
and desalted with 0.1% formic acid in water for 5 min at 100
μL/min. The trap column was placed in line with a lipid trap
column (Waters VanGuard; 1.7 μm C18 particles, 2.1 mm × 5.0
mm) directly connected to the analytical column (Waters BEH
1.7 μm C18 particles, 1.0 mm × 100 mm). The peptides were
eluted with an 8−40% gradient of acetonitrile in 0.05% formic
acid (pH 2.5) over 12 min at a ﬂow rate of 40 μL/min.
Mass spectral analyses were carried out on a Waters QToF
Premier equipped with a standard ESI source and lock mass
calibration using [Glu1]-ﬁbrinopeptide B (200 fmol/μL). The
mass spectrometer was operated with a capillary voltage of 3.5
kV, a cone voltage of 40 V, a source temperature of 80°C, a
desolvation temperature of 175°C, and desolvation gas at 600
L/h. Each 0.5 s scan spanned m/z 200−2000 with an interscan
delay time of 0.05 s. Spectra were collected in positive ion mode
and processed with MassLynx software. Undeuterated sample
controls for both GGCX-nanodiscs and empty nanodiscs were
analyzed in triplicate using a Waters MSE acquisition method.
Identiﬁcation of peptic peptides from MSE data was performed
using ProteinLynx Global Server 2.4 processing software
operated with a custom protein sequence library and non-
speciﬁc enzyme digestion speciﬁcity. Relative deuterium uptake
curves were generated using HX-Express software49 for peptides
identiﬁed in two out of three replicate injections. Deuterium
incorporation was not corrected for back-exchange, represent-
ing relative, rather than absolute changes in deuterium levels.48
The error between biological replicates with this experimental
system was characterized previously33,50 and similarly here did
not exceed ±0.15 Da at each time point. For this work,
diﬀerences in the relative deuterium level between propeptide-
bound and unbound GGCX greater than ±1.0 Da were
reported as having a distinguishable change in protein
conformation. Relative deuterium uptake curves for all
identiﬁed GGCX peptides are reported in Supplemental Figure
S2, Supporting Information for sample conditions with and
without the incorporation of consensus propeptide.
■ RESULTS
Formation of GGCX-pCon-Nanodiscs. GGCX-nano-
discs33 and GGCX-pCon-nanodisc complexes were prepared
using a 1200:20:1 ratio of DOPC/MSP1D1/GGCX protein.
The consensus propeptide (Kd = 0.083 ± 0.005 nM at 4°C)
51
was chosen as a target substrate based on its high binding
aﬃnity for GGCX. Homogenous self-assembly of GGCX-
pCon-nanodiscs was evaluated by size-exclusion chromatog-
raphy (Figure 1) where propeptide-bound GGCX-nanodiscs
(peak II) were isolated from an unassociated aggregate (peak I)
and empty nanodiscs (peak III). Puriﬁed protein standards for
GGCX (∼94 kDa, lane A) and MSP1D1 (24 kDa, lane B) were
provided to identify protein components in concentrated size-
exclusion fractions (Figure 1, gel inset). A ﬂuorescently labeled
consensus propeptide analogue (FpCon; 2.6 kDa) was used to
demonstrate incorporation of pCon into GGCX-nanodiscs. A
comparison of chromatographic features between the visible
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spectrum at 492 nm (orange) and an overlaid absorbance
spectrum at 280 nm (blue) revealed that the high aﬃnity
ﬂuorescently labeled substrate selectively incorporates into
GGCX-nanodiscs (peak II) with only a small fraction shown to
aggregate in an unassociated complex at the void volume of the
chromatographic separation (peak I).
Fluorescence anisotropy was used to determine the
stoichiometric ratio of pCon to GGCX in embedded nano-
discs.52 In the absence of a buﬀer solution containing detergent
or excess phospholipid, the titration of puriﬁed GGCX-
nanodiscs against a constant concentration of FpCon followed
an analogous stoichiometric anisotropy proﬁle to that of
microsomal GGCX, suggesting one propeptide molecule is
incorporated into one active GGCX-nanodisc (data not
shown). The ability to incorporate and isolate monoisotopic
GGCX-pCon-nanodiscs provides a sophisticated near-native
working environment for elucidating dynamic conformational
changes of GGCX and co-substrate interactions involved in the
vitamin K cycle. For the remainder of the work presented,
GGCX-nanodiscs were prepared with the non-ﬂuorescein-
labeled consensus propeptide (pCon).
Modiﬁcations to In Vitro GGCX Activity Assay. GGCX-
nanodisc catalytic functionality was conﬁrmed by monitoring
carboxylation of the pentapeptide substrate FLEEL after protein
incubation at 25°C for up to 24 h (Figure 2). For microsomal
GGCX, the assay was carried out with optimized ratios of lipid,
detergent, and detergent-solubilized KH2 phylloquinone to
maximize catalytic eﬃciency. The formation of GGCX-nano-
discs, however, provides a water-soluble environment no longer
stable in the presence of excess detergent.53 As a result, the
water-soluble KH2 menadione analogue was utilized in the
absence of excess lipid and detergent to improve catalytic
eﬃciencies by increasing the solubility and reactivity with the
active domain of the nanodisc-embedded GGCX. While GGCX
microsomes lose catalytic functionality almost immediately
upon exposure to ambient conditions, GGCX-nanodiscs remain
in a protected environment preventing loss of activity for several
hours at 25°C (Figure 2). In both microsomal and GGCX-
nanodisc samples, incorporation of the high-aﬃnity pCon
substrate maximized levels of carboxylation activity at 25°C.
Gel electrophoresis protein banding patterns of microsomal
GGCX at the 24-h time point (Figure 2, lane 1) indicates that
enzymatic inactivation coincides with the formation of high
molecular weight protein aggregates in the absence of protein
stabilization (nanodisc or propeptide). Incorporation of GGCX
into nanodiscs, however, overcomes many of the inherent
complications notorious for microsome assemblies, enabling
monomeric solubilization and conservation of catalytic activity
with and without pCon (lanes 2 and 4, respectively). Nanodiscs
thus provide a platform in which to study the structural and
functional recognition of membrane protein complexes in a
catalytically active and structurally protected phospholipid
environment. To maintain optimal GGCX activity and limit
the formation of oligomers, all HX labeling experiments were
performed within 4 h of nanodisc assembly.
Hydrogen Exchange Mass Spectrometry Analysis of
GGCX-Nanodiscs. The continuous labeling nanodisc−HX MS
workﬂow, as previously reported,33 was optimized to include
cholate disassembly of the nanodiscs, ZrO2 removal of sample
phospholipid, and temperature-controlled UPLC separation. In
the current work, the nanodisc−HX MS platform was used to
characterize protein−substrate interactions by measuring local
changes in HX (i.e., deuterium uptake) for the GGCX-pCon-
nanodisc complex relative to GGCX-embedded nanodiscs in
the absence of pCon. Time-resolved deuterium incorporation
into GGCX was monitored for duplicate biological preparations
of GGCX-nanodisc complexes. Forty-nine peptic peptides were
unambiguously identiﬁed in GGCX with quality MS deuterium
proﬁles for all time points in both sample forms (see
Supplemental Figure S2, Supporting Information), constituting
a linear sequence coverage of 42% (see Figure 3). Overlapping
peptides were identiﬁed in multiple regions, providing addi-
tional support for uptake trends in small sequence intervals.
Signature peptic proﬁles of the membrane scaﬀold protein
(MSP1D1)50 were monitored to provide a system control for
evaluating experimental performance and distinguishing pep-
tides unique to the embedded protein, in this case GGCX (data
not shown).
Figure 1. Size-exclusion chromatograms (SEC) overlaying self-
assembled GGCX-FpCon-nanodiscs at 280 nm (blue) and 492 nm
(orange). Chromatographic peaks labeled (I), (II), (III) correspond to
labeled SDS-PAGE gel lanes (inset). GGCX (∼94 kDa) and MSP1D1
(24 kDa) puriﬁed protein standards are in gel lanes (A) and (B),
respectively.
Figure 2. GGCX stability at 25°C monitored by catalytic activity.
Activity was measured by the incorporation of radiolabeled 14C as
GGCX carboxylates a small pentapeptide substrate FLEEL in the
presence of propeptide, KH2, oxygen, and NaH
14CO3. In all sample
systems, the 100% active control is recorded at time zero. Stability is
compared between microsomal GGCX (red) and GGCX-embedded
nanodiscs (blue) with (◊) and without (⧫) pCon. The fractionated
proteins from the 24-h time point at 25°C are represented by SDS-
PAGE for each sample.
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Among the GGCX peptides identiﬁed, six noteworthy
regions (Figure 3, colored amino acid residues) were evaluated
to assess changes in solvent accessibility and/or hydrogen
bonding resulting from GGCX−pCon association. Comparing
the magnitude and rate of deuterium exchange into the same
peptide under two diﬀerent conditions (in this case with and
without pCon) highlights local changes in protein conformation
and dynamics as a result of that binding. Whereas some regions
Figure 3. Sequence coverage plotted on the predicted topology map of GGCX. With the exception of six colored peptides of interest, sequence
coverage is indicated by amino acids colored in dark gray. Amino acids in white were not observed in these experiments. A single disulﬁde bond is
indicated between amino acid residues cysteine 99 and cysteine 450. Glycosylation sites are highlighted in light blue. Deuterium uptake curves are
provided for six representative peptic peptides where the highlighted color of the peptide sequence is matched to the color of the box surrounding the
curve. The average deuterium incorporation from duplicate biological replicates is shown for GGCX-nanodiscs without (blue) and with (orange)
pCon.
Figure 4. Deuterium diﬀerence diagrams illustrating GGCX topology images at consecutive HX labeling intervals from 10 s to 4 h. The diﬀerence in
deuterium incorporation for each GGCX peptide was calculated at individual labeling time points by subtracting the deuterium level for the pCon-
bound GGCX from the deuterium level of unbound GGCX. The change in deuterium incorporation is plotted on the predicted topology map of
GGCX where a major (>2.0 Da), minor (1.0−2.0 Da), and no distinguishable change (<1.0 Da) corresponds to the colors red, yellow, and gray,
respectively. Residues in white were not observed with conﬁdence in duplicate biological and sample preparations for both experimental conditions
(with or without propeptide). Neighboring and overlapping peptides were used for deuterium uptake pattern validation (see also Supplemental
Figure S2, Supporting Information). Glycosylation sites are highlighted in light blue.
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of GGCX (e.g., residues 8−21) are shown to have a nearly
indistinguishable diﬀerence (<1.0 Da) in deuterium uptake after
interaction with propeptide, other regions have subtle, yet
important changes in deuteration at early (e.g., residues 643−
660) or late (e.g., residues 701−713) labeling times throughout
the analysis.
Peptic peptides from the predicted transmembrane helices
within the phospholipid bilayer were identiﬁed. The GGCX
peptide LFLPYSHF (residues 375−382) is located in the exit
region of the ﬁfth transmembrane domain. Consistent with
structural predictions, the representative transmembrane
domain peptide displays little exchange, indicative of a
solvent-protected environment and a stable α-helical structure
that spans the lipid membrane. Small changes in deuteration
between free and pCon-associated-GGCX were cumulatively
below the experimental cutoﬀ (<1.0 Da) and thus classiﬁed as a
nonimportant change in the context of this work (see
Experimental Procedures for explanation of experimental
cutoﬀ).
In the presence of propeptide, GGCX residues 395−401
display a modest, yet reproducible decrease in deuterium
uptake, indicating a more solvent-protected conformation in
this region across all time points. The substrate-induced
reconﬁguration of GGCX as measured by HX MS indicates
either a direct or indirect propeptide contact. These ﬁndings
correlate well with previous reports31,32 implicating the
involvement of GGCX residues within the 393−404 sequence
region in both glutamate and propeptide substrate binding.
The most noteworthy change in GGCX HX upon pCon
association was found for peptides spanning GGCX residues
491−507. This region had relatively high levels of deuteration in
the unbound state, but upon addition of propeptide there was a
66% decrease in deuterium uptake at the 10 s time point.
Despite evidence of a more solvent-protected environment in
the pCon-associated GGCX complex, a steady increase in
deuterium content toward the unbound protein form was
shown at longer labeling times, suggesting ﬂexibility in the
propeptide-bound conformation.
The topology diagrams in Figure 4 were compiled to provide
a visualization of conformation changes between free and pCon-
bound GGCX-nanodiscs over a continuous labeling experiment
(10 s to 4 h). GGCX peptides are denoted by color in each
diagram to represent a diﬀerence in the magnitude of deuterium
exchange between each condition. Diﬀerences are classiﬁed as
major (>2.0 Da), minor (1.0−2.0 Da), and no distinguishable
change (<1.0 Da) where larger values represent greater
protection from exchange in the propeptide-bound state. At
the 10 s and 1 min time points, binding of the propeptide to
GGCX results in many minor conformational changes. By the 5
min time interval, residues 180−186, 328−342, 395−401, 423−
431, 484−490, 491−507, 507−516, 532−543, and 717−730
each continue to be characterized by a minor (1.0−2.0 Da)
diﬀerence in deuterium incorporation. As the labeling experi-
ment progressed, the uptake in deuterium for the majority of
identiﬁed peptides leveled oﬀ to a steady-state value similar to
that of the unbound form of the protein. This trend can most
notably be seen as the topology coloration shifts from an
abundance of minor deuterium diﬀerences (yellow) at the early
labeling time-points to a population occupied mostly by
changes in deuteration below our threshold for diﬀerentiation
(gray) at the 30 min and 4 h time points. The exception to this
trend is for GGCX peptide 491−507, which appears highly
protected throughout the entirety of the deuterium labeling
experiment. Thus, in addition to the known propeptide binding
domain, these experiments support the notion that many
regions within GGCX are inﬂuenced by the binding of the
propeptide.
Hydrogen Exchange Mass Spectrometry Analysis of
the Consensus Propeptide. The deuterium uptake of the
propeptide itself was also shown to change upon binding to
GGCX of embedded nanodiscs. Figure 5A overlays a peptide
isotopic distribution proﬁle for the pCon substrate (green) and
GGCX-pCon-nanodiscs (orange) as a function of deuteration
time. The centroid mass value at each time point for both
experimental conditions provides a graphical comparison
between the unbound and bound forms of the peptide (Figure
5B). Variants (<0.5% peptide content) of the pCon sequence
(additions, deletions, and single amino acid replacements as
measured by amino acid analysis) were monitored. No evidence
for binding or structural protection of these variants was
identiﬁed in HX MS experiments, ruling out the potential for
false contributions to GGCX deuterium uptake patterns.
In the free form, pCon demonstrated high levels of deuterium
incorporation indicating little protection from the solvent. This
ﬁnding was further conﬁrmed by circular dichroism (data not
shown), which indicated that the consensus propeptide exhibits
little or no secondary structural features. Upon association with
GGCX-embedded nanodiscs, deuterium incorporation of the
pCon peptide changes from that of an unstructured form to one
that is protected from exchange, indicating the formation of new
backbone amide hydrogen bonds or shielding from solvent of
amide hydrogens in the propeptide upon binding to GGCX.
While characterized by decreased deuteration in the protein-
bound form, deuterium uptake increased at longer labeling
times, indicating that the GGCX−pCon association remains
ﬂexible and ﬂuid. Future investigation of deuterium uptake
proﬁles for propeptide incorporation may provide a conforma-
tional comparison of structural changes that occur in GGCX in
the presence of diﬀerent propeptide substrates and under
conditions in which other co-substrates are added to the
GGCX-nanodisc platform.
Figure 5. Mass spectra (A) during the HX time course for the pCon
substrate (green) and GGCX-pCon-nanodiscs (orange). At each time
point interval from 10 s to 4 h, the isotopic centroided mass of the
peptide distribution was determined to create the deuterium uptake
plot (B). The y-axis maximum represents the total possible
exchangeable backbone amide hydrogens in the consensus propeptide
sequence.
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■ DISCUSSION
This study of GGCX-pCon-nanodiscs demonstrates the
application of HX MS for the investigation of membrane
protein−ligand interactions in a nanodisc phospholipid environ-
ment. Despite the urgent need for detailed structural
information of membrane proteins, biophysical characterization
is severely limited by sample incompatibilities with analytical
methods, the scarcity of nonperturbing model membrane
systems, and the diﬃculties of crystal structure determination
of protein−lipid samples. Nanodisc technology provides a
controlled assembly mechanism in which membrane proteins
are incorporated as single molecules into a near-native
phospholipid environment, optimized for a given trans-
membrane protein of interest. By utilizing nanodisc bilayers
to supply a native-like membrane environment, HX MS can
provide an analytical platform to investigate dynamic structural
changes of membrane proteins in response to natural
ﬂuctuations or environmental stimuli in solution. The method-
ology was described in a previous report33 and continues to be
recognized as an emerging technology in the advancement of
membrane proteins54 with HX MS methods.55
Modeling GGCX−VKD protein interactions is of particular
interest toward understanding of the complex biochemical
mechanism of the vitamin K cycle. In the present study, we
attempted to elucidate localized changes in GGCX protein
dynamics of potential catalytic domains over a continuous
deuterium-labeling experiment as a means to study structural
changes that occur in GGCX upon the binding of propeptide.
Our results are consistent with previous observations regarding
the location of propeptide interaction with GGCX, while
providing additional information on cooperative structural
inﬂuences in other regions within GGCX.
To convey conﬁdence in our model system, we speciﬁcally
sought details to evaluate the binding of a propeptide to GGCX.
Results indicated that the GGCX−pCon complex was
successfully incorporated into nanodiscs (Figure 1). These
assembled complexes were structurally stable and catalytically
active over extended time periods thereby providing an
advantage over traditional microsomal solubilization methods
(Figure 2). Conﬁrming propeptide speciﬁcity for GGCX-
nanodiscs and extended stability of the protein complex
aﬃrmed that the conformational information derived from
deuterium labeling was highly reﬂective of the active complex in
vivo. Nanodisc analysis by HX MS thus provides conformational
characterization of transmembrane protein complexes that is
otherwise extremely diﬃcult to obtain by other methods.
Changes in deuterium exchange are represented as time-
dependent uptake plots constructed for individual peptides of
GGCX (Figure 3; Supplemental Figure S2, Supporting
Information) and the pCon substrate (Figure 5). Deuterium
uptake curves were subsequently used to compile a topology
map of GGCX while maintaining strict guidance to
reproducibility in matched identiﬁcations (±0.15 Da) for
duplicate biological sample preparations with and without
pCon. Despite limited GGCX sequence coverage (42%),
diﬀerential topology diagrams (Figure 4) provide a tremendous
amount of information on protein conformation between free
and pCon-bound GGCX-nanodiscs over the continuous
labeling experiment. Ongoing improvements to the HX MS
nanodisc technology, including improved sample preparation,
chromatographic separation, MS sensitivity, ion mobility, and
dynamic range will further increase peptide coverage and
provide more information regarding protein dynamics for large
transmembrane systems like GGCX.
In the absence of a three-dimensional protein structure,
diﬀerential topology maps of individual GGCX peptides
obtained periodically over a continuous labeling time course
yields a dynamic viewpoint of substrate binding on GGCX
conformation. In all experiments, the addition of pCon resulted
in decreased protein ﬂexibility (increased solvent protection or
hydrogen bonding) in many regions of GGCX as indicated by a
decrease in the level of deuterium uptake. For all GGCX
peptides identiﬁed, 61% were characterized by changes in
deuteration levels >1.0 Da for a single time point in the
continuous labeling reaction. The most pronounced enhance-
ment in deuterium exchange was primarily located around the
known glutamate binding site (393−404)31,32 and the
propeptide binding region (495−513).11,12 Within these
domains, two GGCX peptic peptides, residues 395−401
(maximum Δ+1.5 Da) and 491−507 (maximum Δ+5.6 Da),
revealed extensive protection from deuterium incorporation
when the pCon substrate was present. For the 491−507
peptide, and neighboring peptides 484−490 and 507−516,
pronounced changes in deuteration over longer time intervals
are consistent with direct binding and sustained alteration of
local solvent accessibility or hydrogen bonding networks,56
indicating little variability in the GGCX−pCon-bound con-
formation. Interestingly, the appearance of important and major
protection at a distance from the known propeptide binding
site, namely, in the glutamate binding site (residues 393−404),
provides direct biophysical evidence for the relationship
between the anchoring of the VKD propeptide and the catalytic
carboxylation of glutamic acid residues. This observation is
likely due to either a close proximity of these two parts of the
protein or an allosteric mechanism that connects them.16,52,57
Evaluation of the rate and magnitude of change in GGCX
deuteration upon propeptide binding provides evidence of
conformational changes that modify solvent exposure or
hydrogen bonding interactions as the protein adopts a
catalytically stable structural state.
While the propeptide and Gla binding domains in GGCX
have been extensively characterized, several subtle diﬀerences in
GGCX structure were noted at varying deuteration time points,
enabling predictions of associated peptide proximities within
the three-dimensional structure. Major (>2.0 Da) changes in
deuterium uptake upon propeptide binding are observed for
peptides 257−272, 643−660, and 717−730 at the 10 s and 1
min labeling times points. While the C-terminal peptides 643−
660 and 717−730 are accepted to be distal from the
carboxylation active site, a recent report identiﬁed carboxylation
of glutamic acid residues in GGCX peptides 625−647 and 729−
758 in the presence of vitamin K.58 Although it is unlikely that
C-terminal carboxylated Glas are required for catalysis,59 the
present HX MS data suggest substrate-induced reorientation of
GGCX peptides 643−660 and 717−730 conform to a more
solvent-protected environment at initial labeling time points.
Peptide 728−758, however, measured a diﬀerence in deuterium
uptake below the ±1.0 Da threshold for peptide structural
diﬀerentiation. Future investigations of this system in the
presence of additional co-substrates (e.g., vitamin K) and a full-
length VKD protein may provide information supporting the
mechanism linking the location of the GGCX Gla domain in the
ER lumen to enzymatic function in VKD protein carboxylation.
A quantum model reported by Wu et al.60 proposes the
relative orientation of GGCX and VKOR transmembrane
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proteins as a heterodimer colocalized in the ER membrane
allowing eﬃcient oxidation and reduction of vitamin K during
the vitamin K cycle. In accordance with predictions of
transmembrane helix unit topologies for GGCX and VKOR,
compatibility of the heterodimer proposed model was validated
using previous biochemical and mutational data. In this system,
the relative orientation of carboxylation-dependent GGCX
residues L394,32 W501,61 G537,62 G558,62 and T59163 are
located in close proximity to the C-terminus of GGCX and the
N-terminus of VKOR.60 In correlation with this proposed
structure, GGCX peptides 395−401, 491−507, 532−543, and
554−568, as identiﬁed in our HX MS experiments, exhibited
structural reorientation in the form of diminished solvent
exposure and/or hydrogen bonding upon the incorporation of
propeptide substrate. While peptides with known involvement
in glutamate (395−401) and propeptide (491−507) binding
are represented by changes in deuteration over longer time
periods, peptides 532−543 and 554−568 reveal changes in
deuteration at shorter time intervals indicating temporary
alterations of the local solvent accessibility upon the binding of
propeptide.
On the opposing side of the heterodimer complex, GGCX
residues W157,63 H160,64 and K21825 are predicted to reside in
close proximity to the napthoquinone unit of vitamin K and the
surface of the membrane in the ER lumen.60 This placement is
shown to be consistent with models implicating H160 and K218
as critical residues in the deprotonation of vitamin K
hydroquinone and the initiation of the carboxylation
reaction.25,64,65 The close proximity of these residues to the
hydrophobic transmembrane domain, however, results in
minimal recovery of peptic peptides within these regions and
limits evaluations by HX MS. Improvements to sample
denaturation and digestion may enhance peptide recovery of
potentially informative regions of GGCX.
Bridging the gap between experimental data and theoretical
predictions, HX MS allows comparisons of relative deuterium
incorporation for speciﬁc peptides across the GGCX polypep-
tide backbone, thereby providing both spatial and temporal
information on structural inﬂuences and conformational
changes induced by substrate introduction in previously
diﬃcult-to-explore regions of the GGCX structure. Similar to
the T591K and W157R mutations, D31N is an inherited VKD
coagulation factor autosomal recessive bleeding disorder
associated with defects in either GGCX or VKOR.63 While
wild-type GGCX activity was exhibited for the D31N mutation,
W157R and T591K activities were 8% and 0% that of wild-type
GGCX, respectively.63 Located on the opposite side of the
membrane where propeptide binding occurs, peptide 25−40
undergoes minor (1.0−2.0 Da) changes in deuterium
incorporation at the 10 s and 1 min labeling time points.
Although D31 may not be directly involved in propeptide
binding, HX MS data support a structural dependence on
substrate association. A similar phenomenon of indirect
cooperative structural inﬂuences on GGCX structure upon
propeptide binding is observed for GGCX residues 180−186,
257−272, 328−342, 423−431, 685−692, and 701−713. For the
majority of these peptides, a decrease in deuterium incorpo-
ration occurs at the early labeling time points. At longer time
intervals, these peptides showed an eventual loss of protection
consistent with long-range changes aﬀecting the ﬂexibility and
dynamics of the entire protein. Visualization of protein
dynamics through time-resolved topology maps not only
provides a proﬁle of GGCX protein dynamics over time, but
also aids in understanding the mechanism by which GGCX
domains cooperate to create a stable three-dimensional
structure for VKD carboxylation.
In the absence of a fully resolved crystal structure for GGCX,
the analysis of changes in deuterium uptake upon propeptide
binding yields a structural storyline uniting conformational
organization in GGCX and functional roles involving substrate
binding for carboxylation. Improvements in HX MS technology
will lead to the desire to analyze larger and more complex
proteins and multiprotein systems. In this work, we expand
upon this methodology to include an investigation of
membrane protein−ligand interactions by HX MS. The
investigation of the transmembrane protein GGCX aims to
target the structural relationship between GGCX and co-
substrates involved in the vitamin K cycle as a means to develop
therapeutics for blood coagulation disorders. Using the
nanodisc−HX MS platform, this study represents the ﬁrst
application, to our knowledge, of this strategy for investigating
speciﬁc conformational changes in propeptide-bound GGCX.
Future experiments aimed to improve sample throughput will
not only provide a universal methodology for membrane
protein investigation but also will reveal information in the
mostly uncharted territory of membrane protein dynamics.
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